Keybanc Reiterates Overweight Rating on West Pharmaceutical Services, Inc. (WST)

Market Context

West Pharmaceutical Services, Inc. operates in the Healthcare sector. The stock currently trades at $366.69 with a market capitalization of $19.6B. The stock has gained 27.2% over the past 52 weeks.

Analyst coverage from Keybanc provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for West Pharmaceutical Services, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for West Pharmaceutical Services, Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 02, 2026	Keybanc	Overweight	N/A
Jun 09, 2026	Barclays	Overweight	N/A
Jun 02, 2026	Stephens & Co.	Overweight	N/A
May 29, 2026	Morgan Stanley	Equal-Weight	N/A
Apr 27, 2026	Barclays	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View WST Stock Page